Adverum Biotechnologies Management
Management criteria checks 3/4
Adverum Biotechnologies' CEO is Laurent Fischer, appointed in Jun 2020, has a tenure of 4.5 years. total yearly compensation is $1.55M, comprised of 43.4% salary and 56.6% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $333.76K. The average tenure of the management team and the board of directors is 2.9 years and 4.6 years respectively.
Key information
Laurent Fischer
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 43.4% |
| CEO tenure | 4.5yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Nov 18We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13
Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$94m |
| Jun 30 2024 | n/a | n/a | -US$100m |
| Mar 31 2024 | n/a | n/a | -US$113m |
| Dec 31 2023 | US$2m | US$672k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$126m |
| Jun 30 2023 | n/a | n/a | -US$133m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$3m | US$646k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$155m |
| Dec 31 2021 | US$9m | US$621k | -US$146m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$138m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | US$22m | US$327k | -US$118m |
Compensation vs Market: Laurent's total compensation ($USD1.55M) is above average for companies of similar size in the US market ($USD650.00K).
Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.
CEO
Laurent Fischer (60 yo)
4.5yrs
Tenure
US$1,546,477
Compensation
Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.5yrs | US$1.55m | 0.34% $ 333.8k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 2yrs | US$2.30m | 0.048% $ 47.4k | |
| Chief Operating Officer | 3.5yrs | US$903.02k | 0.13% $ 131.7k | |
| Chief Development Officer | 2.9yrs | US$799.36k | 0.026% $ 25.4k | |
| Chief Medical Officer | less than a year | US$94.20k | 0% $ 0 | |
| Chief Technology Officer | 1.3yrs | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior VP & General Counsel | 3.4yrs | US$1.33m | 0.031% $ 30.7k | |
| Chief People Officer | 5.3yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.9yrs | no data | no data | |
| Senior Vice President of Quality | 3.2yrs | no data | no data | |
| Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations | no data | no data | no data |
2.9yrs
Average Tenure
56.5yo
Average Age
Experienced Management: ADVM's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.5yrs | US$1.55m | 0.34% $ 333.8k | |
| Independent Director | 5.6yrs | US$111.70k | 0.050% $ 49.0k | |
| Independent Director | 4.7yrs | US$106.70k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Chairman | 7.8yrs | US$163.80k | 0.042% $ 41.8k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 3.8yrs | US$99.20k | 0% $ 0 | |
| Independent Director | 4yrs | US$106.70k | 0.024% $ 23.7k | |
| Independent Director | 5.6yrs | US$99.20k | 0.062% $ 61.6k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Director | less than a year | no data | no data |
4.6yrs
Average Tenure
63yo
Average Age
Experienced Board: ADVM's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 23:41 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adverum Biotechnologies, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |